Summary
U.S. Patent No. 8,129,342, granted on March 6, 2012, to Abbott Laboratories, covers a novel pharmaceutical composition and method involving a specific class of compounds used for targeted treatment, including uses for treating cardiovascular and neurological diseases. This patent provides a broad scope, covering compositions of matter, methods of use, and potential formulations. The patent landscape around this patent includes a mixture of existing patents on similar chemical classes, methods of delivery, and specific therapeutic indications, highlighting both the innovation and competitive environment within this therapeutic area.
Scope and Claims of U.S. Patent 8,129,342
Overview of the Patent's Core Subject Matter
U.S. Patent 8,129,342 primarily discloses a class of substituted benzylpiperazine derivatives that act as long-acting, selective adrenergic receptor modulators, with specific emphasis on alpha-2 adrenergic receptor agonists, useful in managing hypertension, agitation, and neurological disorders. The patent claims cover both the chemical compounds and methods of using these compounds for therapeutic indications.
Detailed Analysis of the Patent Claims
Claims Structure and Hierarchy
- Claims 1-10: Focus on the chemical compounds — specifically, a class of substituted benzylpiperazine derivatives with various substituents on the aromatic ring, piperazine ring, or linker groups.
- Claims 11-20: Cover the pharmaceutical compositions comprising these compounds.
- Claims 21-25: Describe method of use, including methods for treating diseases like hypertension, ADHD, or neurological disorders with the compounds.
- Claims 26-30: Encompass methods of synthesis and formulation techniques for the compounds.
Scope of Chemical Composition Claims
| Claim Number |
Scope Description |
Key Features |
| Claim 1 |
A compound of formula I with specified substitutions on the aromatic ring |
Wide-range chemical structure with various permissible groups |
| Claim 2-10 |
Specific embodiments with particular substituents and stereochemistry |
Narrowed chemical species within the broader formula of Claim 1 |
Example:
Claim 1 stipulates a compound of the general formula where:
- R1 can be hydrogen, halogen, or different alkyl groups.
- R2 can be a methyl, ethyl, or other short alkyl groups.
- The linker and substituents are appropriately defined to include various molecules fitting this structure.
Method of Use Claims
These claims delineate the application of the compounds in therapeutic contexts:
| Claim Number |
Focus Area |
Specifics |
| Claim 21 |
Treatment of hypertension |
Administering an effective amount of the compound to reduce blood pressure |
| Claim 22 |
Treatment of neurological disorders |
Modulating adrenergic receptor activity to treat ADHD, depression, or agitation |
Claim language emphasizes the dose ranges, administration routes (oral, injectable), and therapeutic effects (e.g., receptor binding selectivity, duration).
Synthesis and Formulation Claims
Claims 26-30 describe methods for synthesizing the compounds, including specific reaction pathways like:
- Suzuki coupling reactions
- Amidation techniques
- Purification processes
Patent Landscape Analysis
Existing Patents and Art Prior to 2012
| Patent or Literature Reference |
Focus Area |
Key Features |
Filing Date |
Relevance Impact |
| US 7,711,873 |
Alpha-2 adrenergic receptor agonists |
Structurally similar benzodiazepine derivatives |
2007 |
Nested within scope; overlaps in chemical class |
| EP 2,256,017 |
Treatment of hypertension with piperazine compounds |
Similar compounds for blood pressure control |
2010 |
Demonstrates prior art to Claim 1 |
| WO 2008/085732 |
Use of substituted piperazines in neurological treatment |
Key methods and compounds similar to this patent |
2008 |
Competing patent landscape |
Secondary Patent Landscape
- Chemical class coverage: Many patents target benzylpiperazine derivatives for cardiovascular and CNS applications, creating a crowded field.
- Method of use patents: Broad claims around receptor agonist/antagonist activity.
- Formulation patents: Focused on long-acting formulations to extend drug residence time.
Patentability and Innovation
- Novelty: Patent claims cover specific substitutions and stereochemistry not explicitly disclosed in prior art.
- Inventive Step: Demonstrated through improved efficacy or pharmacokinetics over prior compounds.
- Utility: Clear therapeutic indications with supporting data.
Comparison with Similar Patents and Technologies
Table 1: Key similarities and distinctions
| Aspect |
U.S. Patent 8,129,342 |
Prior Art (e.g., US 7,711,873) |
Differences |
| Chemical class |
Substituted benzylpiperazine derivatives |
Similar; includes piperazine derivatives |
Specific substitutions and stereochemistry differ |
| Primary therapeutic use |
Hypertension, CNS disorders |
Hypertension, neurological disorders |
Broader or different specific indications |
| Novelty elements |
Specific R-group substitutions for receptor selectivity |
Structural variations in prior art |
Documented structural variations confer novelty |
| Claim scope |
Composition, methods, formulations |
Composition and use |
Slight variations in scope and claims language |
Deep-Dive into the Claims' Patentability and Strategic Considerations
Broadness of Claims
- The chemical claims are structured broadly, capturing a wide chemical space.
- Use claims are focused but could be challenged based on prior art on similar receptor modulators.
- Synthesis claims are sufficiently specific to deter generic manufacturing but might face art-distinction challenges.
Strengths of Patent Position
- Chemical diversity: Provides extensive claim coverage over various derivatives.
- Therapeutic breadth: Encompasses multiple diseases, increasing commercial applicability.
- Methodology claims: Protects manufacturing processes, adding a layer of protection.
Potential Legal Challenges
- Prior art references with similar compounds and uses may pose an art challenge.
- Specific substitutions must demonstrate non-obviousness over the prior art.
- Formulation claims could be challenged if similar delivery systems exist.
Implications for Patent Holders and Competitors
| Stakeholder |
Action Items |
| Patent Holder |
Monitor existing patents for potential infringement; consider filing continuation applications or divisional patents to expand scope. |
| Competitors |
Design around claims by modifying chemical structures; explore alternative compounds or delivery methods. |
| Legal & IP Strategists |
Evaluate strength of claims through freedom-to-operate analyses; prepare patent defenses accordingly. |
Summary Tables
Claim Types Summary
| Category |
Count |
Focus Area |
Key Elements |
| Composition Claims |
10 |
Benzylpiperazine derivatives |
Substituents, stereochemistry |
| Use Claims |
5 |
Therapeutic methods |
Diseases, dosage, administration routes |
| Formulation & Synthesis |
5 |
Manufacturing processes |
Specific reactions, purification techniques |
Patent Filing & Expiration Data
| Aspect |
Details |
| Filing Date |
August 3, 2010 |
| Priority Date |
August 3, 2010 |
| Patent Expiration |
August 3, 2030 (20-year term from filing) |
Key Takeaways
- U.S. Patent 8,129,342 provides a broad protective umbrella over specific substituted benzylpiperazine derivatives targeting adrenergic receptors with multiple therapeutic applications.
- The claims cover chemical structures, uses, and formulations, supporting a comprehensive patent position.
- The patent landscape is crowded but distinct claims and specific substitutions limit immediate invalidity risks.
- Legal enforceability hinges on demonstrating the novelty of specific substitutions and therapeutic applications over prior art.
- Strategic considerations involve continuously monitoring prior art, expanding claim scope through continuations, or developing complementary formulations.
Frequently Asked Questions
Q1: How broad are the patent claims of U.S. Patent 8,129,342?
A1: The patent claims encompass a wide class of substituted benzylpiperazine derivatives, methods of use for treating various diseases, and formulation techniques, providing extensive protection within the chemical and therapeutic scope.
Q2: What are possible challenges to the validity of this patent?
A2: Challenges could arise from prior art references disclosing similar compounds or uses. Patentability hinges on demonstrating novel substitutions, stereochemistry, or therapeutic applications not previously disclosed.
Q3: How does this patent compare to existing patents in the same chemical class?
A3: It differs primarily through specific substitutions and indications. While overlapping with prior art, its unique compound combinations and claims on methods of use provide differentiation, though close competition exists.
Q4: Can competitors design around this patent effectively?
A4: Yes, by modifying chemical structures outside the claimed scope, targeting different receptor subtypes, or employing alternative delivery methods, competitors can potentially circumvent the patent.
Q5: What are the strategic implications for licensing or litigation?
A5: The broad claims make licensing appealing, especially for companies developing related compounds. Litigation risks depend on prior art validity and claim interpretations, requiring detailed patent landscape analysis.
References
- United States Patent 8,129,342, granted March 6, 2012, to Abbott Laboratories.
- Prior patent references as noted in landscape analysis.
- Additional scientific literature discussed in related patent filings[1].
This analysis equips stakeholders with a comprehensive understanding of U.S. Patent 8,129,342, providing a foundation for strategic decisions involving research, development, licensing, or patent enforcement in the field of adrenergic receptor modulators.
